The Arthritis Advisory Committee will be in the unusual position of having to advise FDA March 12 on whether it should lift the clinical holds it has placed on ongoing clinical trials of anti-nerve growth factor agents, perhaps using risk mitigation proposals advanced by sponsors Pfizer, Regeneron and J&J.
The panel will be asked to vote on